Regeneron plans to share advancements from blood cancer pipeline
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American Society of Hematology (ASH) Annual Meeting from 9-12 December 2023 in San Diego, US.
The abstracts intended to be shared include research across six investigational medicines, spanning eight difficult-to-treat blood cancers and disorders. Ten of the abstracts will share updated data and analysis of the company’s most advanced investigational blood cancer medicine, odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). The company will also share clinical trial results for this indication.
Other presentations include data supporting linvoseltamab, for example primary end point results from the phase 2 LINKER-MM1 trial in heavily pretreated patients with multiple myeloma, as well as results from three phase 2 trials assessing pozelimab in combination with Alnylam Pharmaceuticals’ cemdisiran in patients with rare blood disorder paroxysmal nocturnal haemoglobinuria.
L Andres Sirulnik MD PhD, senior vice president of Translational and Clinical Sciences, Hematology at Regeneron, commented: “We are fusing our legacy of innovation with our deep scientific expertise in haematology to advance research across multiple modalities as we aim to ultimately make a meaningful impact in patients’ lives. Our data at ASH are a testament to our progress towards this ambition. In addition to new results from our pivotal trials evaluating odronextamab and linvoseltamab, we are presenting findings on our growing blood disorders pipeline. Further, our presentations span emerging measures of disease that contribute to a deeper understanding of these advanced conditions, which in the future could form the basis of response-directed treatment paradigms.”
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has …
Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg …